Puretech Health PLC ORD 1P

PureTech Health plc, founded in Boston, Massachusetts, is a clinical-stage biotherapeutics company focused on discovering, developing, and commercializing innovative biotechnology and pharmaceutical solutions. The company's mission is to create new classes of medicine to transform the lives of patients suffering from devastating diseases. PureTech Health is currently advancing several therapeutic candidates, including LYT-100 for idiopathic pulmonary fibrosis (IPF) in Phase 3 trials and LYT-200, an IgG4 monoclonal antibody targeting galectin-9 for treating solid tumors and hematological malignancies in Phase 1/2 trials.

Notable figures associated with PureTech Health include its leadership team and scientific advisors, who are experts in biotechnology and pharmaceutical development. The company has attracted significant investment from leading healthcare investors, enabling it to advance its pipeline of therapeutic candidates. PureTech Health's key achievements include progressing multiple candidates through various clinical trial phases and making impactful strides in addressing unmet medical needs. The company’s overall impact lies in its potential to bring transformative treatments to market, offering hope to patients with serious health conditions.